elosulfase alfa

(redirected from Vimizim)

elosulfase alfa

(el-oh-sul-fase al-fa),


(trade name)


Therapeutic: orphan drugs
Pharmacologic: enzymes
Pregnancy Category: C


Treatment of patients with Mucopolysaccharidosis type IVA (MPS IVA, Morquio A Syndrome).


Consists of an enzyme produced by recombinant DNA technology that hydrolyzes sulfate from galactose-6–sulfate or N-acetyl-galactosamine-6–sulfate. Lack of this enzyme in Mucoplysaccharidosis results in intracellular accumulation of glycosaminoglycans (GAG) producing widespread cellular, tissue and organ dysfunction.

Therapeutic effects

Decreased accumulation of GAG, decreased end organ dysfunction and improved musculoskeletal performance MPS IVA.


Absorption: IV administration results in complete bioavailability.
Distribution: Taken up by cells.
Metabolism and Excretion: Unknown.
Half-life: Initially—7 min ; after prolonged treatment—35.9 min (due to neutralizing antibodies).

Time/action profile (blood levels)

IVunknown†end of infusionunknown
†Improvement in musculoskeletal function may take wk-mos.


Contraindicated in: None noted.
Use Cautiously in: Concurrent acute febrile/respiratory illness (↑ risk of life threatening complications of hypersensitivity reaction); Sleep apnea (supportive measures should be available during infusion); Obstetric: Use during pregnancy only if potential benefit justifies potential risk to fetus; Consider maternal need for elosulfase alfa and potential adverse effects to infant; Pediatric: Safe and effective use in children <5 yr has not been established.

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)
  • headache (most frequent)


  • abdominal pain (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)


  • chills (most frequent)
  • fever (most frequent)
  • hypersensitivity reactions including anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Intravenous (Adults and Children ≥5 yr) 2 mg/kg once weekly; pretreatment with antihistamines with/without antipyretics recommended.


Solution for intravenous use (requires further dilution): 5 mg/5ml single-use vial

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of anaphylaxis (cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, nausea, abdominal pain, retching, vomiting). Discontinue infusion and manage symptomatically. May occur 30 min to 3 hr after start of infusion and as late as 47th infusion.
  • Evaluate airway patency and risk of sleep apnea. Provide supplemental oxygen or continuous positive airway pressure (CPAP) during sleep and infusion in case of acute reaction or extreme sleepiness induced by antihistamine.

Potential Nursing Diagnoses

Deficient knowledge, related to medication regimen (Indications)


  • Pre-treat with antihistamines, with or without antipyretics, 30–60 min prior to start of infusion.
  • Intermittent Infusion: Determine number of vials required. Diluent: Dilute with 0.9% NaCl to a final volume of 100 mL for patients weighing less than 25 kg or 250 mL for patients weighing 25 kg or more. Solution is clear to slightly opalescent and colorless to pale yellow; do not administer solutions that are discolored or contain particulate matter. Gently rotate to mix; do not shake or agitate. Use diluted solution immediately or refrigerate up to 24 hr followed by up to 24 hr at room temperature during infusion.
  • Rate: Infuse over at least 3.5 (100 mL) or 4.5 hr (250 mL) through a low-protein binding infusion set with a low-protein binding 0.2 micron in-line filter.

Patient/Family Teaching

  • Explain the purpose of elosulfate alfa to patient.
  • Advise patient to notify health care professional immediately if signs and symptoms of anaphylaxis occur.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Encourage patient to enroll in Morquio A Registry to collect data on pregnant women with MPS IVA treated with Vimizim by contacting MARS@bmrn.com or call 1-800-983-4587.

Evaluation/Desired Outcomes

  • Decreased end organ dysfunction and improved musculoskeletal performance.
References in periodicals archive ?
Nine-year-old Gracie Mellalieu is one of just five people in Wales to be diagnosed with Morquio Syndrome and for the last three years has been trialling the PS200,000 a year drug Vimizim, which her family claim has changed her life.
Patients with Morquio syndrome A and lysosomal acid lipase (LAL) deficiency are first in line to benefit from the emergence of novel treatments, with the respective launches of Vimizim (BioMarin's elosulfase alfa) and Kanuma (Alexion/Synageva's sebelipase alfa) in 2014 and 2015 respectively.
The first rare pediatric disease voucher was offered to the pharmaceutical firm BioMarin in February this year after its rare disease drug Vimizim won FDA approval.
cell lymphoma, and BioMarin's Vimizim for Morquio syndrome.
For the last three years she has been receiving the drug Vimizim as part of a clinical trial funded by its makers BioMarin, and is the only person in Wales to take part.
BioMarin also announced this week that the European Commission approval of VIMIZIM, an enzyme replacement drug for the treatment of MPS IVA, a lysosomal storage disorder.
Gracie suers from Morqiuo Syndrome, and her family has spent months campaigning for the drug Vimizim to be funded by the NHS.
Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome).
Eight-year-old Gracie Mellalieu, who suffers from Morquio A Syndrome, is trialling a drug called Vimizim, currently funded by BioMarin.
is seeking Canadian approval for its enzyme replacement therapy, Vimizim.